The prevalence of metabolic syndrome and its components in benign and malignant nodular thyroid diseases

• Published in: Pamukkale Medical Journal Vol. 12; no. 3; p. 423
• Main Authors: CAN, Sevinc, Cuneyd ANIL, NAR, Asli, GURSOY, Alptekin
• Format: Journal Article
• Language: English
• Published: Denizli Pamukkale University, Facutly of Medicine 30-09-2019
• Subjects: Homeostasis; Insulin; Metabolic syndrome; Thyroid gland
• ISSN: 1309-9833; 1308-0865
• DOI: 10.31362/patd.558418

Purpose: Metabolic syndrome (MetS) is a condition harboring a group of metabolic abnormalitieswhere insulin resistance (IR) plays a major role. The aim of our study is to evaluate MetS and its components in patients with benign and malignant nodular thyroid disease (NTD). Materials and methods: A total of 800 patients (430 euthyroid benign nodular and 370 euthyroid malignant NTD) were analyzed for MetS and its components. Serum insulin levels and IR estimated by homeostasis model assessment (HOMA-IR), as well as other MetS parameters were evaluated. Results: Metabolic syndrome was detected in 59.8% of 800 patients. There was no significant difference between benign and malignant NTD groups related to the prevalence of the MetS (61.4% in benign nodular group, 57.8% in malignant nodular group, p>0.05). The most common MetS component was abdominal obesity (65%), followed by low HDL-C level (64.8%), and high blood glucose level (30.8%). When patients with benign and malignant NTD were evaluated separately, the occurrence of the MetS components were found in similar frequency in the benign group compared to the overall average. In the malignant group, it was determined that low HDL-C level was the most common and high blood pressure was the least common component. There was no significant difference between benign and malignant NTD groups in terms of insulin levels and HOMA-IR. Conclusions: The results suggest that patients with NTD have significantly increased MetS prevalence compared to patients without NTD. However, there was no significant difference between benign and malignant NTD in this respect.